Normal Human Serum - Complement (1.0 mL)
Uniform pool of human serum complement that has been characterized for levels of complement activation fragments as well as CH50.
Product Specifications
Citations | 35 |
---|---|
Description |
Uniform pool of human serum complement that has been characterized for levels of complement activation fragments as well as CH50. |
Storage | Store at or below –70˚C |
Form |
Frozen Liquid |
Concentration | N/A |
Applications |
See citations and technical data sheet for application info. |
Ordering Information
Catalog Number | A111 |
---|---|
Catalog Number (CE) | N/A |
Size | 1.0 mL |
Price (USD) | $80.00 |
Price (EURO) | 70,00 € |
Contact us
US Phone | +1 (858) 552 1100 |
---|---|
EU Phone | +353 (91) 412 474 |
US Email | contact-us@quidelortho.com |
EU Email | contact-emea@quidelortho.com |
- Specifications
- Citations
- Certificate of Analysis
Specifications
Description |
Uniform pool of human serum complement that has been characterized for levels of complement activation fragments as well as CH50. |
---|---|
Size | 1.0 mL |
Storage |
Store at or below –70˚C |
Form | Frozen Liquid |
Concentration | N/A |
Applications | See citations and technical data sheet for application info. |
Purity | N/A |
Source |
Human blood |
Activity | N/A |
Molecular Weight | N/A |
Background |
Because the anticoagulants used in the preparation of plasma (EDTA, ACD and even heparin) can interfere with complement activation in vitro, serum has long been used as a human complement source for experimentation. Many commercially available sera, however, are not processed appropriately to conserve complement activity. Lyophilization and plasma recalcification can raise background levels of complement split products (SC5b-9 or TCC, iC3b, Bb, C4d and particularly the anaphylatoxins C3a, C5a and C4a) and decrease CH50. Sera, however, must be processed quickly and correctly to prevent complement turnover. For this reason, sera obtained from blood banks and other large pools may not be suitable for many experimental procedures. Conversely, in house serum draws are complicated by several factors including the necessity of maintaining standardized pools of complement for ongoing experimentation and the confidentiality requirements relating to infectious disease testing. QuidelOrtho Normal Human Serum Complement is designed to address these specific issues. |
Citations
Title | Year | Applications | Sample Species | Sample | Sample Details |
---|---|---|---|---|---|
2014 | ELISA |
Bacteria |
Salmonella enterica |
||
2018 | FC |
Bacteria |
Streptococcus pneumoniae |
||
2013 | FC |
Bacteria |
Salmonella enterica |
||
2008 | CDC Assay |
Cell Culture |
Daudi Cells |
||
2008 | CDC Assay |
Cell Culture |
Ramos Cells |
||
Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity |
2011 | CDC Assay |
Cell Culture |
sLea antigen |
positive and negative cell lines |
2013 | CDC Assay |
Cell Culture |
RC-K8 cells |
||
2013 | CDC Assay |
Cell Culture |
SU-DHL-4 cells |
||
2013 | CDC Assay |
Cell Culture |
Huh7.5 Cells |
||
2013 | CDC Assay |
Cell Culture |
OPM-2 cells |
||
Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers. |
2013 | CDC Assay |
Cell Culture |
MDA-MB-231 Cells |
|
Real time assays for quantifying cytotoxicity with single cell resolution. |
2013 | CDC Assay |
Cell Culture |
Jeko-1 Cells |
Lymphoma cells |
Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus. |
2014 | CDC Assay |
Cell Culture |
Daudi Cells |
|
Comparability of a three-dimensional structure in biopharmaceuticals using spectroscopic methods. |
2014 | CDC Assay |
Cell Culture |
WIL2-S cells |
|
2015 | CDC Assay |
Cell Culture |
CHO Cells |
||
2016 | CDC Assay |
Cell Culture |
KIT225/K6 cells |
||
2017 | CDC Assay |
Cell Culture |
CHO cells |
||
Recruitment of Factor H to the Streptococcus suis Cell Surface is Multifactorial. |
2016 | Phagocytosis assay |
Cell Culture |
THP-1 Cells |
|
2012 | TER Measurements |
Cell Culture |
RPE Cells |
||
Engineered antibody Fc variants with enhanced effector function |
2006 | CDC Assay |
Human |
WIL2-S cells |
Rituximab |
2011 | CDC Assay |
Human |
B-Cells |
||
Humanization and characterization of an anti-human TNF-α murine monoclonal antibody. |
2011 | CDC Assay |
Human |
Peripheral blood mononuclear cells |
|
2012 | CDC Assay |
Human |
WIL2-S cells |
CD-20 AbX antibody |
|
2012 | CDC Assay |
Human |
Peripheral blood mononuclear cells |
||
A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. |
2017 | CDC Assay |
Human |
A549 cells |
|
A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. |
2017 | CDC Assay |
Human |
WIL2-S cells |
|
2021 | Complement Activation Assay |
Human |
Disc Tissue |
||
Analytical Similarity Assessment of ABP 959 in Comparison with Eculizumab Reference Product. |
2021 | ELISA |
Human |
Serum |
|
2014 | ELISA |
Human |
Serum |
||
2013 | FC |
Human |
Serum |
Staphylococcus epidermidis incubated |
|
2017 | FC |
Human |
Peripheral blood mononuclear cells |
||
2013 | Mass Spec |
Human |
Red Blood Cells |
||
Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury |
2009 | TER Measurements |
Human |
ARPE-19 Cells |
|
Complement-Opsonized HIV-1 Overcomes Restriction in Dendritic Cells. |
2015 | ELISA |
Virus |
HIV |
Purified |
2012 | VCA |
Virus |
HIV |
Purified |